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Dechelation (Transmetalation)
Consequences and Safety Concerns With the Linear Gadolinium-Based Contrast
Agents, In View of Recent Health Care Rulings by the EMA (Europe),
FDA (United States), and PMDA (Japan)
Val M. Runge, MD
Abstract: The issue of dechelation (transmetallation) in vivo after administration
of the linear gadolinium-based contrast agents, and potential safety concerns, is
considered on the basis of an extensive, focused literature review. Early indica-
tions of potential problems included the high level of excess ligand used in the
formulation of 2 agents (indeed the 2 least stable thermodynamically) and inter-
ference with laboratory tests when blood was drawn from patients relatively soon
after administration of these same agents. The advent of nephrogenic systemic
fibrosis in the late 2000s raised additional major concerns.
The correlation in 2014 of dentate nucleus hyperintensity on precontrast
T1-weighted scans with multiple prior injections of linear gadolinium chelates,
in patients with normal renal function, has driven subsequent research concern-
ing dechelation of these agents in vivo. Unexpectedly high levels of gadolinium
in the bone, skin, and liver have been found long term after administration, in an-
imal models and in humans, although the latter data are limited. Bone may serve
as a long-term reservoir, with a residual excretion phase for gadolinium after in-
travenous injection of the linear agents due to a subsequent slow release from
bone.Many different patient populations could be vulnerable and potentially later
develop clinical symptoms, although at this stage there are only limited data and
small retrospective uncontrolled studies. Possible vulnerable populations include
children, menopausalwomen, patients with osteoporosis (who are predisposed to
fractures and often slow to heal or heal poorly), those receiving multiple doses,
those with proinflammatory conditions, moderate renal dysfunction, or an unde-
fined genetic predisposition. Of particular concern would be nephrogenic systemic
fibrosis–like symptoms—including particularly pain and skin/joint symptoms, or
disease related to the incorporation of gadolinium in hydroxyapatite in bone, in
small subgroups of patientswith a not yet defined propensity and/or cofactor. These
concerns have led towithdrawal of the linear agents from the largest clinical market,
Europe, with the exception of the hepatobiliary agents for delayed liver imaging, an
indication that cannot be fulfilled by the current macrocyclic gadolinium chelates
(for which these concerns do not apply).
Key Words: contrast media, magnetic resonance, dentate nucleus, safety,
toxicity, gadolinium-based contrast agents, brain, bone, skin
(Invest Radiol 2018;53: 571–578)
T he gadolinium-based contrast agents (GBCAs) used in magneticresonance imaging (MRI) can be differentiated on the basis of their
thermodynamic and kinetic stability in vivo, which parallels that estab-
lished in vitro.1,2 Structural differences play a major role, with the linear
chelates less stable than the macrocyclic agents. The linear chelates can
further be divided into 2 groups, nonionic and ionic, with the former the
least thermodynamically stable.3 Dechelation, specifically release of
the gadolinium ion, can occur in vivo as a consequence with the less
stable agents, and has been studied in depth in recent years as safety
concerns mounted regarding the least stable GBCAs. An interplay be-
tween thermodynamic and kinetic stability governs gadolinium release,
with the macrocyclic agents markedly more stable due to their kinetic
stability, which the linear agents lack. Reflecting the importance of this
fundamental issue, the literature is replete over the years during the
history of the development of the GBCAs—including in the very first
published articles—with statements such as “the general aim was to find
a compound that remained stable in vivo,”4 “the design of intravenous
agents depends upon the ability to reduce the toxicity of the agent by
chelating or complexing the paramagnetic metal ion…is a highly stable
chelate that does not undergo metal exchange in vivo,”5 and “the safety
of the gadolinium chelates is largely based on their stability in vivo,”6
indeed the first comes from Weinmann's original landmark article de-
scribing the development of gadopentetate dimeglumine. Gadolinium
is a rare earth metal not normally found as a trace element in the human
body. It is toxic to mammals when present in water-soluble salts, both
acutely (mostly by blocking of calcium channels) and chronically (due
to profibrotic and proinflammatory effects).7–9 This review focuses on
the issue of dechelation with the GBCAs, examining 6 key issues. Cov-
ered in sequence are excess of chelate in the formulation of the agents,
interference with analytical tests, gadolinium retention and excretion,
the fate of gadolinium in the body and potential toxicity, possible
chronic symptoms and syndromes, the status regarding regulatory ac-
tion and changes in approval in the major 3 markets in the world
(Europe, the United States, and Japan), and the concern regarding pos-
sible iatrogenic disease.
Excess Ligand
High levels of excess ligand were used in the formulation of
the least 2 stable GBCAs, the linear nonionic agents, to reduce
dechelation, with the efficacy therein debatable.
The formulations of many, but not all, of the gadolinium chelates
that have been developed for clinical use contain excess ligand.10 The
quantity of excess ligand varies widely, with 2 outliers, gadodiamide
and gadoversetamide.1 The first is formulated with 12mg/mL excess li-
gand (5%)—specifically Ca-DTPA-BMA (sodium salt), and the second
with 28.4mg/mL excess (10%)—specifically Ca-DTPA-BMEA (sodium
salt). The next closest agent in terms of excess ligand is gadoxetic acid
disodium, which is formulated with 1.0 mg/mL excess ligand (0.5%).
The other approved agents feature either low amounts (gadopentetate
dimeglumine 0.4, gadoteridol 0.2, and gadobutrol 0.5 mg/mL—for these
3 agents, all equivalent to 0.1% excess ligand) or no excess ligand
(gadoterate meglumine, gadobenate dimeglumine) in the formulation.
The original formulation of gadopentetate dimeglumine contained
0.2 mg/mL excess ligand, which was very early in development doubled
to 0.4 mg/mL. This change reduced the dose-dependent, transient eleva-
tion in serum iron and bilirubin seen early after injection, with a maxi-
mum at 8 hours postinjection.11 It is of historical interest to note that in
the clinical trials performed for approval purposes with gadodiamide
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blood samples were only collected at one time point postinjection, pre-
sumably at 24 hours (and thus would not have seen this change).12
The development of the nonionic linear chelates was controver-
sial due to the knowledge that these derivatives of DTPAwere suscepti-
ble to dechelation, in addition to possible breakdown of the ligand
itself.13 Ironically, an argument was put forth in early development that
the addition of this degree of excess ligand (5% to 10%) would enhance
the intrinsic safety of such complexes, with release of gadolinium ion
from the complex admitted to be responsible for toxicity and hypothe-
sized to be a consequence of transmetallation with zinc, calcium, and
copper.14 Research published in 1995 confirmed that gadodiamide as
formulated with excess ligand led to lower (but still high) residual tissue
gadolinium, in experimental animals, when compared with the agent
without the excess ligand, with dechelation and changes due to the pres-
ence of excess ligand explaining these results.15 The presence of this
degree of excess ligand, with gadodiamide, also improves the acute
tolerance (median lethal dose). It was not however until 2008 that
the addition of such large amounts of excess ligand was indeed shown
to reduce dechelation in in vivo–like conditions.1 And, although it did
reduce the gradual release of dissociated “free Gd”—for the 2 nonionic
linear chelates, as evaluated in human serum at pH 7.4, to approximately
20% (with 15 days incubation), this level was still more than a factor of
10 times greater than that seen with the other linear chelates. As noted
in the early investigation of nephrogenic systemic fibrosis (NSF) and
its etiology, it is likely that the excess ligand only confers an advantage
early on after injection of any agent, since other endogenous metallic ions
such as copper, zinc, and calcium in vivo can be chelated, according to
their affinity for the ligand and their local concentration.16
Interference With Analytical Tests
Gadodiamide and gadoversetamide, after injection, interfere
with blood laboratory tests, in particular the measurement of
serum calcium.
It was first published in 199517 that gadodiamide injection inter-
fered with the determination of serum calcium on laboratory colorimet-
ric tests. Despite an additional report in 1999 explaining this effect as
the consequence of transligation (exchange of ligand) for Gd between
the ligand of gadodiamide (DTPA-BMA) and the compound used for
the colorimetric test (o-cresolphthalein complexone or OCP),18 clini-
cians remained largely unaware of this issue until 2003. In that year,
an article was published demonstrating spurious decreased serum cal-
cium measurements in patients receiving gadodiamide, with “critical”
hypocalcemia in many (and more common in renal insufficiency).
Inappropriate treatment with intravenous calcium was reported in
7 patients.19 Spurious hypocalcemia was deemed by the authors to
be “a potentially important cause of unnecessary and potentially
dangerous medical interventions.”
Care needs to be exercised, given the findings just cited, when
interpreting results of laboratory tests for patients who have recently
received either gadodiamide or gadoversetamide, which of all the
approved MR contrast media are the 2 most frequently implicated
and having the greatest effect.9,20 With normal renal function, the
elimination half-life of these agents is approximately 90 minutes. To
diminish the likelihood of any interference, it is suggested towait 24 hours
between administration of these contrast agents and blood specimen
collection. The waiting period for patients with renal insufficiency nec-
essarily would be substantially longer, with the elimination half-life of
these agents being much longer than 24 hours in patients with severely
reduced renal function.21
The most prominent interference is with the measurement of
calcium, angiotensin-converting enzyme, and serum iron.19,22,23 Re-
sults depend upon the specific analytical method used. The interfer-
ence seen after gadodiamide and gadoversetamide administration
has been concluded to be due to the dissociation of these gadolinium
chelates, with macrocyclic chelates not producing any interference with
analytical methods.24 For example, in the presence of OCP (used for the
calcium colorimetric assay), it has been shown that gadodiamide disap-
pears and the free ligand and a new complex Gd-OCP appear.24 In the
case of circulating angiotensin-converting enzyme, an effect of the
added free ligand, with gadodiamide and gadoversetamide, is likely.22
In regard to the determination of serum iron and problems therein prin-
cipally with gadodiamide and gadoversetamide, the situation would
most likely arise only shortly after contrast administration or in patients
with renal impairment. This effect upon the measurement of serum iron
has been shown to occur with all the linear agents tested, and not with
macrocyclic agents.24 Indeed, the thermodynamic stability constant of
DTPA-BMA is higher with iron than for both gadolinium and calcium.
Gadolinium Retention/Excretion
A residual excretion phase, with subsequent slow release from
bone, has been identified for the GBCAs, with the linear nonionic
and to a lesser degree the linear ionic agents having high long-term
levels in bone, skin, and liver.
Upon injection, the GBCAs are distributed in the extracellular
space and eliminated (as was previously thought) unchanged by the
kidneys—with additional elimination in the bile for 2 agents (Table 1).
The blood elimination half-life of the agents in healthy adults is about
90 minutes.10,25 Regulatory information (specifically, for example, the
summary of product characteristics in Europe), however, does not detail
the percentage retained beyond 24 hours, or the subsequent involved
pathways. The presence of a long-lasting residual excretion phase was
first described in 1996,26 being further developed and exemplified in
a 2016 article.27 It is now known that macrocyclic agents undergo a
much faster residual excretion from the body than linear agents. The
mechanism for the long-term retention of the linear agents and their
subsequent slow release from bone in vivo is likely explained by their
dissociation. The existence of substantial bone deposition raises the
possibility of toxicity therein, in part due to bone marrow loss or a
decrease in cancellous bone but also due to the risk of Gd release
in patients with increased rates of bone resorption (eg, osteoporosis
patients and menopausal women).28
Research performed in 1995, well before the recognition of NSF
and the later discovery of focal dentate nucleus accumulation, identified
a separation of whole-body clearance data after 24 hours dependent on
GBCA stability.15 Formulated gadodiamide left the largest % remaining
at the latest time point sampled (14 days, in mice), specifically 0.3%,
followed by gadopentetate dimeglumine, 0.1%, with the 2 macrocyclic
agents evaluated (gadoteridol and gadoterate meglumine) having the
least residual Gd in the body. Although these differences in delayed
biodistribution were identified, the study did not evaluate the form of
the retained Gd. Liver and bone had the greatest detected residual Gd
at the latest time point evaluated, with the residual Gd correlating
(as with the whole-body data) with GBCA stability. For example,
in the femur, 0.01% residual was identified with formulated
gadodiamide, 0.003% with gadopentetate dimeglumine, and below
the limits of detection with the 2 macrocyclic agents evaluated
(gadoteridol and gadoterate meglumine).
In 2009, during the NSF era, Gd deposition in the skin was
studied in experimental animals.29 Using rats, Gd was assayed from
skin biopsies obtained sequentially for a year after intravenous injec-
tion of the GBCAs. The evaluation was limited to the agents with
solely renal excretion. As with the results in other organs in the earlier
radiolabeled study, it was demonstrated that the Gd concentration in the
skin, regardless of time point, correlated with chelate stability. In addi-
tion, in the case of the linear GBCA gadodiamide but not with a mac-
rocyclic GBCA, the presence of dissociated and soluble Gd in skin
and bone was shown by the relaxometry technique.30 Continuing with
a description of the results from the 2009 publication, the less stable
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GBCAs resulted in higher Gd concentrations, with Gd in the skin unde-
tectable in the later time points after administration of the macrocyclic
GBCAs. Not only was delayed clearance noted with the linear GBCAs,
but in addition a plateau in concentration was reached by 60 days with
relatively stable residual amounts thereafter. This was also subse-
quently shown in the brain, with demonstration that Gd is no longer
in its initial molecular form there as well after injection of the linear
agent gadodiamide.31
Of critical importance are biospeciation studies, determining the
form in which gadolinium is present in tissue, which can serve to drive
hypotheses and further research concerning potential acute and chronic
toxicity.1,27,31–33 According to the most common current hypothesis,
GBCAs move from the bloodstream to the cerebrospinal fluid and
thence into the brain. With the linear GBCAs, a portion remains intact
and there is dechelation (transmetallation/transchelation) of the remain-
der.32 The latter leads to soluble Gd (bound to macromolecules),34,35
causing the high signal intensity on T1-weighted scans in the dentate
nucleus, and insoluble Gd (for example as gadolinium phosphate), with
weak or no effect on T1. Acute7,36 and chronic toxicity need to be dis-
tinguished, the latter possibly leading to inflammatory reactions. The
distribution and local concentration of gadoliniumwill differ depending
upon its form and, for the soluble species, the macromolecules towhich
it is bound. Most speciation analysis requires a soluble sample, with ap-
propriate controls needed to ensure that the gadolinium species remain
unchanged during sample preparation.
During the NSF period, very high levels of Gd were also docu-
mented in the skin of these patients. Despite regulatory efforts since
connection of that disease with administration of GBCAs, occasional
patients have been diagnosed in subsequent years.37 Elemental analysis
has been used in at least one such patient for disease diagnosis. It is
important to note, however, that levels in the skin of Gd in 1 patient
(a case report)—who had normal renal function and dentate nucleus
hyperintensity—were shown to be at or above the level demonstrated
in NSF patients.38 The question thus arises whether patients such as
the individual in this case report may manifest NSF-like symptoms.
For example, the patient in question had increased CD34 immunore-
activity in the subcutaneous tissue, indicating inflammation and/or
tissue injury. The patient also had joint contractures; however, with-
out joint biopsy, the association with high gadolinium levels could not
be confirmed or excluded.
Recently, detailed evaluation of midterm (with regards to life-
span, and still in the washout phase of the intact chelate) Gd deposition
in different organs has been performed in rats, comparing the 3 groups
of agents as defined by their relative stability (from lowest to highest),
the linear nonionics, linear ionics, and macrocyclic compounds.31,32,39
At 8 weeks after repeated high doses, skin, bone, and muscle levels of
Gd were greatest with formulated gadodiamide, less with gadopentetate
dimeglumine, and lowest (near control values in skin and muscle) for
the 2 macrocyclic compounds evaluated. This study, as with most
others, measured total Gd by inductively coupled plasma mass spec-
trometry (ICP-MS), with no information provided about the form of
the tissue Gd (dissociated or chelated, soluble or insoluble). Of note
(and specifically different in comparison with skin results), deposition
in the brain was similar for formulated gadodiamide and gadopentetate
dimeglumine, with that for the 2 macrocyclic compounds again near
control values (close to undetectable). No statistically significant
difference was found between the 2 macrocyclic agents evaluated.
Two additional publications show retention in the skin in rats to be
below the limit of quantification or in the same range as controls
for all 3 macrocyclic agents, with one of these 2 articles also providing
data specifically for gadoterate meglumine in juvenile animals.29,40 The
latter confirmed in juvenile animals below the limit of quantification
amounts of Gd at 60 days in bone and liver as well.
In the literature, a 2006 study compares bone deposition in
humans after formulated gadodiamide and gadoteridol administration.41
The study is limited due to the short time frame (1 week) between agent
administration and bone biopsy. In this study, the nonionic linear agent
left approximately 4 times more Gd in the bone as compared with the
macrocyclic agent. A subsequent study showed that osteoporotic patients
exposed to Gd have significantly lower Gd concentrations, raising the
question whether there may be an increased risk of Gd release in sub-
jects with increased rates of bone resorption.28 Large at risk groups
for Gd release from the bone reservoir might thus exist, including oste-
oporosis patients and menopausal/postmenopausal women.
Scant human autopsy data exist to compare with animal stud-
ies. The human studies are also limited to date by the lack of control
for time after the last recorded GBCA administration, as well as the
inability to exclude additional injections in any patient beyond that
available in the medical record of the institution from which the report
was generated.
TABLE 1. GBCAs for Intravenous Injection, Characteristics, Recent Regulatory Changes
Brand Name Generic Name Chemical Structure Stability
2017 and 2018 Regulatory Changes*
Europe United States Japan
Dotarem Gadoterate meglumine Macrocyclic Highest
Eovist (Primovist) Gadoxetate disodium Linear, ionic Intermediate Delayed liver
imaging only
Gadovist (Gadavist) Gadobutrol Macrocyclic Highest
Magnevist Gadopentetate dimeglumine Linear, ionic Intermediate Suspended “For use if a macrocyclic
is not appropriate”
MultiHance Gadobenate dimeglumine Linear, ionic Intermediate Delayed liver
imaging only
(Never approved)
Omniscan Gadodiamide Linear, nonionic Lowest Suspended “For use if a macrocyclic
is not appropriate”
OptiMARK Gadoversetamide Linear, nonionic Lowest Expired No longer available (Never approved)
ProHance Gadoteridol Macrocyclic Highest
*The package inserts have also beenmodified after requests from the respective agencies. This applies to bothmacrocyclic and linear chelates. Thewording is different
between Europe, the United States, and Japan. The difference between macrocyclic and linear chelates is clearly made in Europe and Japan (as well as in Canada,
Australia, and SouthKorea). Only the FDAmandated the same changes in the package inserts for bothmacrocyclic and linear chelates, minimizing the difference between
classes. However, in the required FDAwording, it is noted that gadolinium retention is less with the macrocyclic agents.
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Gadolinium Fate/Toxicity
Possible vulnerable patient populations include children,
menopausal women, patients with osteoporosis, those with renal
failure, those with systemic inflammation, and those receiving
multiple doses. For NSF, fibrosis led to contractures, with collagen
deposition involving nerves likely leading to the burning pain.
Gadolinium in the skin was extensively investigated during the
period that NSF was discovered and linked to GBCA use. Skin biopsies
were consistent with in vivo release (also described using the terms
transmetallation, transligation, and dechelation) of the gadolinium ion
from gadodiamide and its retention in apatite-like deposits.42 The vari-
able delayed onset of disease in NSF patients after gadodiamide injec-
tion and the increasing concentration of Gd in the skin over time
would suggest a solubilization of the Gd species released from the
hydroxyapatite crystals with subsequent binding to circulating mac-
romolecules (this has not yet been demonstrated). As concluded by a
subsequent investigation, NSF is in essence a manifestation of toxicity
from gadolinium released byMRI contrast media, probably in the pres-
ence of cofactors.8,43 It has also been shown that gadodiamide (presum-
ably the released Gd ion) stimulates fibroblast growth (with fibrosis of
the skin, joints, and internal organs defining this disease).44 In NSF,
gadolinium is detected both extracellularly and intracellularly, the latter
in macrophages and fibrocytes. The acidic environment in lysosomes,
after endocytosis, might promote dissociation and subsequent deposi-
tion as insoluble phosphates. Animal studies performed during this
era showed (with formulated gadodiamide) that the same levels of
long-term Gd skin retention were reached whether doses were given
over a short or long period. However, skin lesions were more severe
when doses were given over a short period.29
The changes in muscles, fascia, nerves, and vessels were studied
in depth in affected patients during the NSF era, along with the specific
gadolinium localization. In these studies, musclewas noted to be themost
common organ involved after skin, with CD34-positive cellular fibrosis
seen therein.45 Muscle biopsies showed disease ranging from mild myo-
pathic changes to severe fibrosis, correlating with the degree of muscle
hardening and immobility. Atrophy, infiltration with fibrous tissue, and
increased collagen deposition were seen.46 Thickening of tendons and
periarticular tissues was also noted.47 Skin and muscle fibrosis were
deemed responsible for the contractures seen in NSF. Fibrous bands of
collagen were also noted, invading nerves as well as muscle fibers, caus-
ing neuropathies with both neurogenic and myopathic features.48 A sen-
sory-motor polyneuropathy was thought to be responsible for the burning
pain so characteristic of NSF. Regarding the vessels, perivascular Gd de-
position was noted, with colocalization of calcium and phosphorus.45
Metals in general can be taken up into bone either by active in-
corporation during osteoblasticmediated bonemineralization or by pas-
sive exchange into the bone lattice. Regarding Gd specifically, it is
proposed that hydroxyapatite can incorporate this metal ion.42 Of con-
cern is that Gd incorporation into bone could negatively impact bone
health, as occurs with other metals such as lead. There is the potential
for inhibition of fracture healing and altering the metabolism of osteo-
clasts and osteoblasts responsible for bone remodeling.49–51
Based primarily on animal data, long-term retention of Gd in the
body is thought to be highest in bone (although perhaps not with
gadodiamide, where higher gadolinium concentrations have been noted
in skin).39,52 In bone, as previously noted, Gd can replace calcium in hy-
droxyapatite. Dissociation has been shown to occur in vivo for some
linear chelates, potentially explaining their long-term retention and slow
release from bone. Potential toxicity from such stores in bone warrant
further investigation.27 The release of Gd from the long-term reservoir
in bone could also explain the increased skin Gd concentration observed
on sequential biopsies in some NSF patients, despite the lack of further
GBCA administration, as well as the delayed onset of disease seen in
some NSF cases.42,43,53,54
The long-term reservoir of Gd in bone suggests the possibility of
specific vulnerable patient populations. Postmenopausal women and
pregnant or lactating women have increased bone resorption, which
would predispose these patients to Gd release from bone. The same is
true for osteoporosis. In children, there is increased bone formation,
and this poses the risk of accumulating a larger bone reservoir of Gd.
Patients exposed to multiple linear GBCA doses, whether due to chronic
illness or high-risk screening, would represent a further potential group at
risk, due to accumulation of larger amounts of Gd in bone. Proinflammatory
events, including surgery, could predispose patients in any of these popula-
tions to further risk, in the presence of a long-term bone Gd reservoir. Proin-
flammatory events, along with hyperphosphatemia, were noted in the NSF
period to place dialysis patients at greater risk for the development of NSF.55
The potential for Gd toxicity in the liver has received little atten-
tion to date. This organ likely contains, long-term following linear
GBCA administration, the third largest concentration of Gd, after the
bone and skin. Although not well studied, the lanthanides are known
to cause liver necrosis.7,26
Potential Chronic Symptoms
Questions have been raised regarding possible cutaneous,
musculoskeletal, and pain syndromes linked to GBCA administra-
tion in patients with normal renal function, in small and as yet
undefined subgroups.
There are suggestions of small groups of normal renal function
patients with chronic symptoms from Gd deposition when examining
the scientific literature and the Food and Drug Administration (FDA)
adverse event reporting system. In the latter, there is a clustering of ad-
verse events around cutaneous, musculoskeletal, and pain syndromes.
These symptoms overlap that seen in NSF, raising the concern and in-
creasing the likelihood of an association with GBCA exposure. The
need for the presence of a cofactor for disease development might
explain the low incidence relative to the very high number of con-
trast administrations performed worldwide over the years. Possible
cofactors for the development of disease in the setting of normal re-
nal function include but are not limited to medication interaction
(containing competing metals, such as Ca, Zn, or Cu, favoring
transmetallation), elevated serum phosphate, proinflammatory condi-
tions, and genetic variables.
A case report in 2016 describes 4 patients with normal renal
function developing symptoms within hours to weeks after GBCA ad-
ministration.56 Burning/sharp pain involving the extremities was seen
in all 4 and involved the trunk in 3—symptoms such as that seen in
NSF. Skin thickening was seen in the late stage, also characteristic of
NSF. This work was followed by a report in 25 patients with normal re-
nal function and symptoms presumed related to GBCA administration
receiving chelation therapy.57 A large, statistically significant increase
in urine Gd content was measured in this population after intravenous
Ca-/Zn-DTPA therapy. Of particular note, however, was that 11 patients
of the 25 experienced transient worsening of at least some symptoms,
with the reasons unclear. Caution is suggested in interpretation of this study,
and specifically the urine Gd content. It was not a crossover study
(no placebo). No clear conclusions can be made without the data
from each individual, and the agent(s) administered cannot be veri-
fied with certainty.
Current Health Care Policy in the 3 Largest GBCA
Markets Worldwide
Concern regarding gadolinium release from the linear che-
lates, and potential complications therein, have led to thewithdrawal
of these agents in Europe, with the exception of the hepatobiliary
agents for delayed liver imaging. In the third largest market,
Japan, these agents are to be used only when macrocyclic agents
are not appropriate.
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In the world's largest market for the GBCAs, Europe, in
November 2017, the European Commission adopted the European
Medicines Agency's (EMA's) Committee for Medicinal Products for
Human Use recommendation—the result of a 21-month safety review—
regarding the GBCAs. The whole-body marketing authorizations of the
multipurpose linear GBCAs (Omniscan, Magnevist, and MultiHance)
were suspended (that for Optimark was allowed to lapse earlier during
the year by the manufacturer). Approval was continued, pending possible
further review, for 2 special indications involving linear GBCAs-
Primovist and MultiHance for delayed liver imaging and a dilute formu-
lation/extremely low dose of Magnevist for intra-articular injection. The
option to defer product suspensions for up to 12 months was granted
on the basis of potential unmet medical need and lack of availability of
suitable alternatives on a country basis. Austria and Denmark enacted
these changes in December 2017, France in January 2018, and the
United Kingdom, Germany, and Italy in February 2018.
In the United States, in December 2017, 3 months after an advi-
sory committee meeting, further instructions were issued by the FDA,
leading inMay 2018 to changes in the package inserts and the availabil-
ity to patients of a Medication Guide. The package inserts (prescribing
information in the United States) were changed for all agents, incorpo-
rating the same standard detailed wording and explanation regarding
gadolinium retention. Agents were differentiated into 3 groups on the
basis of the degree of Gd retention. Rare reports of pathologic skin
changes in patients with normal renal function were noted, including
adverse events involving multiple organ systems. Regarding the clinical
consequences of gadolinium retention in patients with normal renal
function, it was noted that these have not yet been established. However,
it was stated that certain patient groups might be at higher risk, specif-
ically those requiring multiple doses over their lifetime, pregnant and
pediatric patients, and patients with inflammatory conditions. Further-
more, the following guidancewas given in terms of a Medication Guide
that should be made available to patients:
“All MRI centers should provide a Medication Guide the first
time an outpatient receives a GBCA injection or when the information
is substantially changed. In general, hospital inpatients are not required
to receive aMedication Guide unless the patient or caregiver requests it.
A health care professional who determines that it is not in a patient's
best interest to receive a Medication Guide because of significant con-
cerns about its effects may direct that it not be provided to that patient;
however, the Medication Guide should be provided to any patient who
requests the information.”
TheMedication Guide for each agent is individualized and avail-
able on the FDAWeb site (https://www.fda.gov/Drugs/DrugSafety/
ucm085729.htm). The following statement was however added for all
agents: “There are different GBCAs that can be used for your MRI
exam. The amount of gadolinium that stays in the body is different
for different gadolinium medicines. Gadolinium stays in the body
more after Omniscan or Optimark than after Eovist, Magnevist, or
MultiHance. Gadolinium stays in the body the least after Dotarem,
Gadavist, or ProHance.”
As of September 15, 2018, Optimark (one of the 2 linear
nonionic gadolinium chelates) will no longer be available on the US
market. Guerbet incidentally acquired the agent as part of its 2015 purchase
of the contrast media and delivery systems business of Mallinckrodt Phar-
maceuticals. Guerbet also allowed the approval for distribution ofOptimark
in Europe to expire in 2017.
As background to the recent Japanese guidance, it should be noted
that only 3 linear gadolinium chelates were ever approved in Japan
(Omniscan, Magnevist, and Primovist), whereas all 3 macrocyclic agents
are approved. InNovember 2017, the decisionwas issued by the Japanese
authorities to restrict the use of the nonspecific linear GBCAs (Omniscan
andMagnevist) to patientswhere there is no other alternative (specifically
when use of macrocyclic agents would not be appropriate). This was
done to allow the use of the 2 linear agents in patients with reactions to
macrocyclic agents. The Japanese decision was based on the higher accu-
mulation in the brain of gadolinium reported with the linear agents. Al-
though a labeling change was made for all 3 linear agents, regarding
the larger amount of gadolinium remaining in the brain as compared with
themacrocyclic agents, the use of Primovist was not restricted. This agent
is the only hepatobiliary gadolinium chelate available in Japan, with high
usage due to the prevalence of hepatocellular carcinoma.
Additional Issues
That dechelation occurs in vivo after administration of the
linear GBCAs is well established. The concern is regarding possible
clinical symptoms, with limited such data and investigations to
date. Identification of the macromolecules that bind the Gd in the
case of linear GBCAs may be the starting point for any investiga-
tion on toxicity.
A major reason that health care authorities in Europe and
Japan have left available to clinicians—but generally only for delayed
hepatobiliary phase imaging—the linear hepatobiliary gadolinium che-
lates is that these were deemed medically necessary, and without com-
parable macrocyclic analogues (also due to the smaller dose used, at
least for gadoxetic acid disodium, and the lower likelihood for repeat in-
jections). The scientific literature is replete with articles demonstrating
the importance in terms of medical diagnosis, lesion characterization,
and response to therapy provided by delayed imaging with the
hepatobiliary linear gadolinium chelates.58–60
Renal function needs to be kept in mind in regard to the potential
for long-term gadolinium deposition (and the degree thereof ) after
administration of the linear chelates. It is clear from the evaluation
of animals receiving such agents that renal dysfunction (with the
correlate in patients being mild or moderate chronic kidney disease)
potentiates deposition of gadolinium not only in the cerebellum but
also in the brain and bones.61 These results are fully consistent with a
prior clinical study,62 thus stressing the translational value of most
nonclinical studies.
Animal studies performed by many different research groups
have definitively established that dechelation occurs after injection
of the linear gadolinium chelates.32 Evidence for such includes the
hyperintensity on imaging of the dentate nucleus (and other structures,
in patients receiving a high number of injections of the linear agents),63
measurement of tissue gadolinium concentration by ICP-MS,64 evalua-
tion of tissue homogenates by gel permeation chromatography,33 and
evaluation of spatial tissue distribution of Gd by laser ablation coupled
with ICP-MS.39
In the development of the gadolinium chelates, it was not
thought that this group of agents would have access to the brain, other
than in disease states, due to the blood-brain barrier. It is now known
that at least one pathway for access to the brain, in normal individuals,
exists—specifically the glymphatic system.65 Further supporting the
study of Taoka and colleagues, an additional nonclinical study revealed
insoluble Gd deposits in specific areas consistent with this path-
way.66 Despite the existence of this pathway, only minute fractions
(<0.001%) of the total gadolinium dose are found in the brain.39 In
addition to the demonstration of this pathway in animals, support
for its existence has been shown in patients, with demonstration of
dentate nucleus hyperintensity 2 to 12 years after intrathecal injection
of gadopentetate dimeglumine.67
Although many articles have been published advocating alterna-
tives to the gadolinium chelates, both development and—even in the
case of already existing products—clinical approval is very unlikely.
First and foremost, the issue of gadolinium deposition has arisen due
to the existence (and widespread use, formerly) of the linear chelates,
with dechelation and focal tissue deposition of gadolinium not seen in
vivo with the macrocyclic agents. The safety profile of the macrocyclic
agents is excellent, as shown by hundreds of millions of injections
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worldwide. Additional reasons that alternative agents are very unlikely
to be developed include cost, toxicity, and the time required in terms of
years needed for approval. For example, even as of 2006, the cost of de-
veloping an agent for diagnostic imaging was estimated to be in the
$200 million range, with the current global market only $500 million/
year in sales.68 Potential toxicity is a problem for proposed newmanga-
nese-based agents and iron particles,69 with hypersensitivity reactions
also a concern for the latter. Off-label use of other agents, for example
as advocated for ferumoxytol,70 does not take into consideration the
significant risk of hypersensitivity reactions, which explains in part
why such agents are not approved for clinical use as contrast media.
As an alternative to the development of iron or manganese agents
for magnetic resonance, improved chelate design—possible due to the
advances in chemistry in the past 30 years—could result in next-
generation GBCAs with markedly higher relaxivity.71 These agents
would need to have a stability matching or improved relative to the cur-
rent macrocyclic agents. Commercial development could be justified
by the use of a lower gadolinium dose yet achieving the same contrast
enhancement as with the current macrocyclic agents, or by keeping
the dose at 0.1 mmol/kg and improving further diagnostic efficacy.72
The incidence of reactions to a product (and specifically that of a
competitor) has often been used by the pharmaceutical industry to influ-
ence market share. Indeed, such an argument was used by 1 company in
defense of its agent (with data from an article subsequently published),
in a failed attempt to justify its continued approval by the EMA in
2017.73 If one considers the gadolinium chelates that have only renal
excretion (excluding the hepatobiliary agents), “to the best of current
scientific knowledge, all of the gadolinium chelates… have the same in-
cidence of severe anaphylactoid reactions.” “This is also true for minor
adverse reactions, the 2 most notable being nausea and hives.”74 If the
incidence of hypersensitivity reactions was indeed lower with one of
the gadolinium chelates, and not just a marketing argument, then the
FDA and EMA approvals would carry such a specific statement. A re-
cent investigation has specifically looked at this question, as many sites
have transitioned from linear to macrocyclic agents. During transition
from 1 contrast agent to another, a transient increase in frequency of hy-
persensitivity-like reactions can be observed, which is well described in
the scientific literature as the “Weber effect.” This is defined as “a tran-
sient rise in reported adverse drug reactions after the introduction of a
new drug to the market, classically peaking within 2 years and declining
thereafter.”75 In such a transition, an increased incidence of reactions
can also be seen with the agent that is being discontinued, with these
observations likely due to an increased awareness to contrast-related
adverse events during the period of transition with increased attention
to documenting such reactions.
The major concern with dechelation is the potential for clinical
symptoms, both short and long term. Gadolinium is not a normal trace
element in the body, and as one of the lanthanide metals can be in its
unchelated form highly toxic. Perinatal exposure to a GBCA in mice
has been shown to induce behavioral changes, more severe with a linear
as opposed to a macrocyclic agent.76 Although attention has been pri-
marily directed toward the potential for clinical symptoms due to depo-
sition in critical brain nuclei, such as the dentate nucleus, the potential
for symptoms due to bone, skin, and liver deposition also exists. In a
single case report, previously discussed, in a patient with normal renal
function who received a very high number of injections of predominantly
linear gadolinium chelates, skin samples demonstrated a very high level
of gadolinium deposition, similar to reported levels seen in patients with
renal failure and NSF.38
A re-evaluation of the NSF data in 2018 shows a profound effect
of the year of market introduction and market share, among other is-
sues, on the assessment of risk (by agent) that was made in the late
2000s.77 In the concluding sentence, it is noted that comparative risk as-
sessments should be primarily based on objective product parameters, in-
cluding specifically and foremost chelate stability. As was hypothesized
in 2007, the etiology of NSF was eventually shown to be caused by the
instability of a gadolinium chelate and dechelation in vivo.16 It should
be noted that NSF-like symptoms of extremity and torso pain have been
described, as previously discussed, in a small number of patients with nor-
mal renal function after gadolinium chelate injection.56 Unfortunately,
all such reports to date are anecdotal. Evidence of dechelation in pa-
tients with symptoms is, however, clear due to the existence of a pub-
lished clinical trial with chelation therapy, also previously discussed.57
Urinary gadolinium content increased significantly in these patients
after administration of Ca-/Zn-DTPA, with improvement in symptoms
for 13 of 25 patients, although symptoms were worse in 2. The mixed
results, together with a transient worsening of some symptoms in
11 patients, may reflect the extensive bone reservoir of gadolinium.
CONCLUSIONS
The gadolinium chelates (also known as the GBCAs) are well
established today as the contrast media for magnetic resonance, with
an excellent overall safety profile. These agents are critical for disease
diagnosis and indeed to clinical medicine worldwide.
Recent findings have again emphasized that within the group of
previously approved agents there is a range of stability, with this being
one key aspect for safety in man. A relatively recent clinical imaging
finding, specifically hyperintensity of the dentate nucleus on unenhanced
scans after multiple doses of the linear gadolinium chelates, has driven
subsequent key research in this area. Many in-depth, well-performed, sci-
entific investigations have now been completed in this area, clarifying
mechanisms and consequences. It is now known that administration of
the linear gadolinium chelates to patients, despite normal renal function,
leads to long-term deposition of gadolinium in the skin, bone, liver, and
brain (with that in the brain occurring with a focal, specific distribution).
Deposition in the bone also serves as a potential reservoir for later release.
Dechelation occurs in vivo with the linear agents, leading to this tissue
gadolinium deposition and raising safety concerns.
In 2016, the question was raised whether clinical practice with
the less stable gadolinium chelates, specifically those that offer no addi-
tional clinical benefit when compared with the approved macrocyclic
agents, would continue due to these issues.78 Today, the linear agents
(excluding hepatobiliary applications) have either been withdrawn or
face continued reduction inmarket share in theworld's 3 largest markets
(Table 1). This is the result of both regulatory actions and patient/
physician pressure. Unfortunately, outside of the industrialized countries,
knowledge concerning these issues can be poor, leading to continued use
of high-risk agents.79 It is interesting in retrospect, but also somewhat
disappointing, to consider that the knowledge of the greater stability
of the macrocyclic chelates was well established by 1989, and indeed
earlier to dedicated researchers in the field, and that it was suggested
at that time that the macrocyclic agents should replace the linear che-
lates due to the improved safety margin.13
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